Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Famotidine on Afimetoran (BMS-986256) PK in Healthy Participants
NCT04470778Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of afimetoran in systemic lupus erythematosus (SLE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 39 days and Area under the plasma concentration-time curve up to 39 days. Started Jul 2020; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04470778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470778.